ARTICLE | Clinical News
OncoHist: Phase I/II started
January 30, 2012 8:00 AM UTC
Xenetic said SynBio began a dose-escalation, Russian Phase I/II trial to evaluate 500, 750, 1,125 and 1,690 mg/m 2 IV OncoHist in 12 patients who do not respond to standard therapy. The companies part...